Acurian’s clinical trial recruitment database hits 70 million

Monday, January 23, 2012 09:37 AM

Horsham, Penn.-based Acurian, a provider of global patient enrollment and retention solutions, has expanded its opted-in database to over 70 million people. These people have self-reported specific ailments and provided permission to be contacted exclusively by Acurian for clinical trial opportunities.

In 2011, Acurian contacted over 18 million people using its proprietary recruitment database, supporting clinical trial enrollment for studies in therapeutic areas including diabetes, opioid-induced constipation, depression, asthma, COPD, back pain, bipolar disorder, female sexual dysfunction and hypertension.

While other recruitment companies and CROs maintain databases typically gathered via online disease communities, the largest of these communities is under four million individuals.

“We have a significant advantage in trial enrollment services due to the sheer size of our patient database and unparalleled access to potential trial participants,” said Rick Malcolm, Acurian’s CEO. “Only a database with this size and scope can contribute hundreds or thousands of patients quickly across multi-protocol studies. Online disease communities are an important part of the new trial landscape, but alone they simply cannot provide the patient demand for increasingly large studies or those with complicated protocol designs.”

Acurian also reported significant growth in global access to patients through both online and offline media channels. Use of social media and online health networks increased over 200% from previous years, leading to hundreds of millions of clinical trial impressions and click-throughs worldwide. Penetration via television and print led to 81% of the U.S. population being exposed to at least one clinical trial opportunity sponsored by an Acurian customer.

“Our industry is struggling to find innovative ways to manage trial costs while completing enrollment on time,” continued Malcolm. “Strategic CRO alliances and new technologies sound promising on the surface, but fall short in our opinion compared to proven solutions that combine far-reaching patient access with enrollment best practices. These solutions are available today and enable our customers to complete enrollment without adding sites or time.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

February 25

Analysts: With market anticipation of Quintiles IPO, other CROs could soon file to go public

National Clinical Trial Network aims to link sponsors, minority patients for trials and access to new therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Sites rate the best
sponsors of 2013

Largest survey response ever puts Biogen Idec, Forest Labs, Bayer at top

As CRO industry
turns 30, a look back
at modest beginnings

Phenomenal growth, strategic partnering highlight evolution
of CROs

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Sized out of big deals,
mid-tier CROs still thriving

Finding market niches, strategies to stay vital in changing research enterprise

Industry leaders embrace disruptive innovations
Despite resistance to change, many exploring data sharing, open-source collaboration

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs